Felix Korell
Overview
Explore the profile of Felix Korell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert M, et al.
Blood
. 2024 Oct;
145(8):823-839.
PMID: 39441941
Antibiotic (ABX)-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In...
2.
Koeckerling D, Reddy R, Barker J, Eichhorn C, Divall P, Howard J, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2437222.
PMID: 39374017
Importance: The frequency and clinical phenotypes of cardiotoxic events in chimeric antigen receptor (CAR) T-cell recipients remain poorly understood given that landmark approval trials typically exclude patients with high-risk cardiovascular...
3.
Derigs P, Schubert M, Dreger P, Schmitt A, Yousefian S, Haas S, et al.
Leukemia
. 2024 Aug;
38(11):2419-2428.
PMID: 39192036
Third-generation chimeric antigen receptor T cells (CARTs) for relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) may improve efficacy compared to second-generation CARTs due to their enhanced CAR design. We...
4.
Xu K, Kessler A, Nichetti F, Hoffmeister-Wittmann P, Scherr A, Nader L, et al.
Liver Int
. 2024 Aug;
44(11):2950-2963.
PMID: 39164890
Background And Aims: Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the intrahepatic (iCCA) or extrahepatic (eCCA) bile ducts with poor prognosis and limited treatment options. Prior evidence highlighted a...
5.
Korell F, Olson M, Salas-Benito D, Leick M, Larson R, Bouffard A, et al.
Sci Transl Med
. 2024 Jun;
16(750):eadk7640.
PMID: 38838132
Approximately 50% of patients with hematologic malignancies relapse after chimeric antigen receptor (CAR) T cell treatment; mechanisms of failure include loss of CAR T persistence and tumor resistance to apoptosis....
6.
Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, Muller-Tidow C, et al.
EClinicalMedicine
. 2024 Mar;
69:102504.
PMID: 38544797
Background: Assessment of cardiovascular risk is critical for patients with cancer. Previous retrospective studies suggest potential cardiotoxicity of CAR T cell therapies. We aimed to prospectively assess cardiotoxicity and the...
7.
Lee W, Graham C, Wiggin H, Nolan H, Graham K, Korell F, et al.
Cytometry B Clin Cytom
. 2024 Feb;
106(3):162-170.
PMID: 38418432
Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and...
8.
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson R, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1859-1877.
PMID: 38393682
Purpose: Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is...
9.
Scherr A, Nader L, Xu K, Elssner C, Ridder D, Nichetti F, et al.
Hepatology
. 2023 Nov;
80(2):278-294.
PMID: 37916976
Background And Aims: HCC is the most common primary liver tumor, with an increasing incidence worldwide. HCC is a heterogeneous malignancy and usually develops in a chronically injured liver. The...
10.
Ruella M, Korell F, Porazzi P, Maus M
Nat Rev Drug Discov
. 2023 Nov;
22(12):976-995.
PMID: 37907724
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic approach for the treatment of patients with chemotherapy-refractory or relapsed blood cancers, including acute lymphoblastic leukaemia, diffuse large...